

2026 Bioshares Biotech Summit - PROGRAM

Wednesday 5 August

11.00am	Golf, Millbrook Resort (25 mins from town)
3.00pm - 6.00pm	Registration Open (QT, Level 4)
4.00pm - 6.30pm	CEO Forum (QT Hotel, Level 5)
6.30pm	Peasants Dinner (The Grille Bar & Restaurant)
6.45pm	CEO Dinner (St Moritz Hotel, next to QT Hotel)

Thursday 6 August (QT Hotel, Level 4)

7.00am - 8.30am	Registration Open
8.30am	Introduction, Housekeeping

Session 1: Leading the Way

Returning to Queenstown, it is fitting to begin with two of the recent successes in the sector commercialising healthcare products based on R&D developed in NZ, followed by three other leading pharmaceutical businesses at different stages of the development cycle.

8.50am - 9.20am	Key Note Address - Brian Ward, CEO of Aroa Biosurgery
9.20am - 9.40am	Jon Pilcher, CEO of Neuren Pharmaceuticals
9.40am - 10.00am	Aaron Gray, CEO of Mayne Pharma
10.00am - 10.30am	Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals
10.30am - 11.00am	Mike Wheatcroft, Director of R&D at Telix Pharmaceuticals

Chair: David Nayagam, E&P

Sponsored by



11.00am - 11.30am **Break**

Session 2: Approaching Inflection Points

Beginning with a company that has recently secured its fifth international licensing deal, these companies are all moving through key inflection points over the next six to 24 months.

11.30am - 11.50am	Nina Webster, CEO of Dimerix
11.50am - 12.05pm	James Agnew, CFO of Aroa Biosurgery
12.05pm - 12.20pm	Gary Phillips, CEO of Syntara
12.20pm - 12.35pm	Steven Gourlay, CEO of Actinogen Medical
12.35pm - 12.50pm	Chris Burns, CEO of Amplia Therapeutics

Chair: Bell Potter Securities

Sponsored by



1.00pm - 2.30pm **Lunch (Level 6, QT Hotel)**

Session 3: Diagnostics Feature

Putting together seven diagnostic/biomarker-based companies into the one session, the presenters have been asked to explain what levels of accuracy and evidence need to be achieved to make a commercially relevant product (and why), for patients, medical professionals and payors to ensure widespread adoption.

2.30pm - 2.40pm	Henk-Jan Boele, CEO of Blinklab
2.40pm - 2.50pm	Leeanne Hinch, CEO of Inoviq
2.50pm - 3.00pm	David Atkins, CEO of Rhythm Biosciences
3.00pm - 3.10pm	Anne-Louise Arnett, CEO of BCAL Diagnostics
3.10pm - 3.20pm	Dayna Louca, Head of Corp. Dev. of Cleo Diagnostics
3.20pm - 3.30pm	David Morris, CEO of Proteomics International
3.30pm - 3.40pm	Peter Meintjes, CEO of Pacific Edge
3.40pm - 4.10pm	Panel Discussion

Chair: Peter Bradley, **Qatalyst**



Sponsored by

4.10pm - 4.30pm **Break**

Session 4: Improving Healthspan

With an ageing population, we have succeeded in extending lifespan—but we have not achieved the same progress in extending **healthspan**. Healthspan refers to the years we live in good health: independent, functional, and free from serious or chronic debilitating diseases. It is no longer sufficient to ask *how long* we live. The more important question is how well we live as we age. The introduction into this topic will feature four companies that are seeking to improve our healthspan.

4.30pm - 4.40pm	Introduction
4.40pm - 5.00pm	Brad O'Connor, CEO of Cogstate
5.00pm - 5.15pm	John Warmbrunn, CEO of Acrux
5.15pm - 5.30pm	David Kenley, CEO of Lateral Pharma
5.30pm - 5.45pm	John Konstantopolous, Co-Founder of Artrya

Chair: Peter Smith



Sponsored by

5.50pm	The Blake Award for Excellence ("The Blakey")
6.00pm	End of Day 1

Sponsored by



7.30pm - 11.00pm **Cocktail Reception (QT Rooftop Bar, Level 6)**



Friday 7 August

9.00am - 9.45am **Master Class 1 (QT, Level 7, Von Room) - Coordinated by Piper Alderman**

When Science Meets the Market: Communicating Under Pressure. A continuous disclosure master class

Continuous disclosure is a challenge for ASX-Listed life sciences companies. "Immediate" disclosure of market-sensitive information demands rapid Board decisions that translate complex science into clear market disclosures while managing multiple stakeholders. The long development timeline presents its challenges. Our master class will provide practical insights on these topics, informed by what the courts have been saying in recent high profile cases. As the ASX has highlighted the sector as a focus area for FY27, now is the time to consider how your disclosure practices measure up. Come along, and bring your questions!

9.45am - 10.15am **Master Class 2 (QT, Level 7 Von Room)**

Topic: Clinical trial risks and financial exposure (coordinated by Liberty insurance group)

DAY 2 Sessions (QT, Level 4)

Session 5: New Kids on the Block

Recently listed companies as well as private companies that will potentially list over the next 18 months will be featured in this session.

10.30am - 10.45am **ASX**
10.45am - 11.00am Philippa Lewis, CEO of **Imunexus**
11.00am - 11.15am Chris Baldwin, CEO of **HaemaLogix**
11.25am - 11.40am Brent Owens, CEO of **Vitrafy**
11.40am - 11.55am Samantha South, CEO of **Patrys**

Chair: Patrick Wales, Endpoints Capital

Sponsored by



Session 6: Improving Oncology Drugs

11.55am - 12.15pm Cheryl Maley, CEO of **Starpharma Holdings**
12.15pm - 12.35pm Peter Smith, CEO of **Racura Oncology**
12.35pm - 12.40pm Christian Toculi, CEO of **FivepHusion**

12.40pm - 1.10pm **Mike Hirshorn Address**

David Williams, Chairman of Kidder Williams

1.10pm - 2.30pm **Lunch**

(1.45pm - 2.25pm) **R&D Tax Reform and Biotech Investment: Perspectives from Industry, Investors and the Sector**

Chair: Kate Mahady, FB Rice (part of the lunchtime break)

Panelists: Seth Lizee (Euroz Hartleys), Nicole van der Weeden (Arovella Therapeutics), Kerri Lee Sinclair (AusBiotech)

Session 7: Fighting Infections

Controlling infectious diseases is a personal and societal health issue that can erupt at any time. The global pandemic was evidence of that. Disrupting antibiotic resistance, rapidly identifying the correct treatment, developing new therapeutics, and developing more efficient technologies are all part of the war against a persistent enemy to our immediate health, longevity and healthspan. The role that some Australian biotechs are playing in helping us win this war will be the core of this session.

2.30pm - 2.45pm Brent Barnes, CEO of **Clever Culture Systems**
2.45pm - 3.05pm Maud Eijkenboom, MD of **Lixa**
3.05pm - 3.20pm Doug Ward, CEO of **Lumos Diagnostics**
3.20pm - 3.35pm James Graham, CEO of **Recce Pharmaceuticals**
3.35pm - 3.50pm David Foster, CEO of **Island Pharmaceuticals**

Chair: Tim Clark, Piper Alderman

3.50pm - 4.20pm **Break**

Sponsored by



Session 8: Lightning Round

In this 'Lightning Round' five biotechs will provide an update on key advances that have occurred within their business over the last 12 months and events to look out for that are coming up.

4.20pm - 4.30pm Rebecca McQuilter, CEO of **Chimeric Therapeutics**
4.30pm - 4.40pm Jason Carroll, CEO of **Entropy Neurodynamics**
4.40pm - 4.50pm Mary-Ann Rennie, CEO of **Emyria**
4.50pm - 5.00pm Tara Speranza, CEO of **Vectus Biosystems**
Chair: Melissa Groom, **IQVIA Biotech**



Sponsored by

Session 9 – Investment Panel

In one of the most popular sessions at the Summit, we will ask leading sector analysts and investors on their views on where the sector is heading, and what stocks attendees should be looking at.

5.10pm - 5.40pm **Investment Panel**
Panelists: Tanushree Jain (Petra Capital), Thomas Wakim (Bell Potter Securities), Jason Segal (The Armchair Analyst), Stuart Roberts (Pitt Street Research), TBC
Chair: Cameron Jones, **Bio101**

Sponsored by



5.40pm **Closing Comments**

6.45pm - late **Conference Dinner (TSS Earnslaw Steamship to Walter Peak)**

Sponsored by



Media partner



IT Partner

